A detailed history of Janus Henderson Group PLC transactions in Novavax Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 60,815 shares of NVAX stock, worth $517,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,815
Previous 60,815 -0.0%
Holding current value
$517,535
Previous $769,000 0.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.89 - $20.97 $95,771 - $516,281
24,620 Added 68.02%
60,815 $769,000
Q1 2024

May 15, 2024

BUY
$3.76 - $6.02 $485 - $776
129 Added 0.36%
36,195 $173,000
Q4 2023

Feb 14, 2024

SELL
$4.8 - $7.67 $523 - $836
-109 Reduced 0.3%
36,066 $173,000
Q3 2023

Nov 14, 2023

BUY
$6.81 - $9.74 $422 - $603
62 Added 0.17%
36,175 $261,000
Q2 2023

Aug 14, 2023

SELL
$6.67 - $9.52 $333 - $476
-50 Reduced 0.14%
36,113 $268,000
Q1 2023

May 15, 2023

BUY
$5.76 - $12.48 $118,056 - $255,790
20,496 Added 130.82%
36,163 $250,000
Q4 2022

Feb 14, 2023

SELL
$8.86 - $25.04 $8 - $25
-1 Reduced 0.01%
15,667 $161,000
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $6,315 - $26,413
347 Added 2.26%
15,668 $286,000
Q2 2022

Aug 15, 2022

BUY
$36.28 - $75.29 $288,643 - $599,007
7,956 Added 108.02%
15,321 $788,000
Q1 2022

May 16, 2022

BUY
$69.73 - $142.9 $513,561 - $1.05 Million
7,365 New
7,365 $542,000
Q4 2021

Feb 14, 2022

SELL
$134.56 - $217.97 $947,840 - $1.54 Million
-7,044 Closed
0 $0
Q3 2021

Nov 16, 2021

SELL
$177.8 - $270.58 $185,089 - $281,673
-1,041 Reduced 12.88%
7,044 $1.46 Million
Q2 2021

Aug 16, 2021

BUY
$121.0 - $257.67 $978,285 - $2.08 Million
8,085 New
8,085 $1.72 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $666M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.